ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

AI Briefing

• – ANKTIVA is now available in Saudi Arabia for bladder and lung cancer patients, marking a significant market entry for ImmunityBio, and is initially approved for BCG-unresponsive non-muscle invasive bladder cancer patients, with potential expansion to lung cancer indications.
• – The commercial availability of ANKTIVA in Saudi Arabia is a testament to the company's efforts to expand its global reach and bring innovative immunotherapy solutions to patients worldwide.
• – ImmunityBio achieved market entry in Saudi Arabia within just two months of establishing its partnership with the MENA region.